On February 26, Brightgene Bio-Medical Technology Co.Ltd(688166) released the performance express for 2021. The company achieved an operating revenue of 1.052 billion yuan in 2021, an increase of 34% year-on-year; The net profit attributable to the owners of the parent company was 244 million yuan, a year-on-year increase of 43.48%; The net profit attributable to the owner of the parent company after deducting non recurring profits and losses was 224 million yuan, with a year-on-year increase of 42.69%.
Brightgene Bio-Medical Technology Co.Ltd(688166) said that during the reporting period, the company has always implemented the business system of integrating API and preparation, combining generic drugs with innovative drugs, and paying equal attention to the international market and the Chinese market. Adhering to the innovation driven development strategy, the company continued to build high-tech barriers and actively carried out global layout. The operating revenue and net profit attributable to the owners of the parent company continued to grow steadily.
